Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,137.73
    +58.87 (+0.73%)
     

  • Bitcoin USD

    63,947.39
    +545.20 (+0.86%)
     

  • CMC Crypto 200

    1,340.42
    -56.11 (-4.02%)
     

  • S&P 500

    5,103.87
    +55.45 (+1.10%)
     

  • Dow

    38,213.36
    +127.56 (+0.33%)
     

  • Nasdaq

    15,933.91
    +322.15 (+2.06%)
     

  • Gold

    2,346.30
    +3.80 (+0.16%)
     

  • Crude Oil

    83.53
    -0.04 (-0.05%)
     

  • 10-Yr Bond

    4.6570
    -0.0490 (-1.04%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Why Shares of Zai Lab Are Dropping Wednesday

Jim Halley, The Motley Fool
·2-min read
Why Shares of Zai Lab Are Dropping Wednesday

Shares of Zai Lab (NASDAQ: ZLAB) were down more than 13% Wednesday morning, a day after the biotech company reported phase 3 trials for an oncology therapy it is developing with NovoCure. Zai Lab's stock is down more than 5% so far this year. Zai Lab said that its tumor treating fields (TTFields) therapy, which uses skin patches to deliver electric fields to areas of the body, when used with standard therapies, met its primary endpoint of three-month improvement in median overall survival (OS) in metastatic non-small cell lung cancer (NSCLC) patients.

Continue reading